ATE198754T1 - Antikörper gegen saugetier-interleukin-4 und peptide verwendbar als antigenen für deren herstellung - Google Patents

Antikörper gegen saugetier-interleukin-4 und peptide verwendbar als antigenen für deren herstellung

Info

Publication number
ATE198754T1
ATE198754T1 AT95108150T AT95108150T ATE198754T1 AT E198754 T1 ATE198754 T1 AT E198754T1 AT 95108150 T AT95108150 T AT 95108150T AT 95108150 T AT95108150 T AT 95108150T AT E198754 T1 ATE198754 T1 AT E198754T1
Authority
AT
Austria
Prior art keywords
antigens
antibodies
production
peptides used
interleukin
Prior art date
Application number
AT95108150T
Other languages
English (en)
Inventor
Frank Lee
Takashi Yokota
Ken-Ichi Arai
Timothy Mosmann
Donna Rennick
Craig Smith
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US06/843,958 external-priority patent/US5552304A/en
Priority claimed from US06/908,215 external-priority patent/US5017691A/en
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ATE198754T1 publication Critical patent/ATE198754T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/247—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5406—IL-4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/66—General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16241—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Auxiliary Devices For Music (AREA)
  • Fertilizers (AREA)
AT95108150T 1985-11-19 1986-11-19 Antikörper gegen saugetier-interleukin-4 und peptide verwendbar als antigenen für deren herstellung ATE198754T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US79966985A 1985-11-19 1985-11-19
US79966885A 1985-11-19 1985-11-19
US06/843,958 US5552304A (en) 1985-11-19 1986-03-25 CDNA Clones coding for human protein exhibiting a broad cellular activity spectrum (human interleukin-4)
US88155386A 1986-07-03 1986-07-03
US06/908,215 US5017691A (en) 1986-07-03 1986-09-17 Mammalian interleukin-4

Publications (1)

Publication Number Publication Date
ATE198754T1 true ATE198754T1 (de) 2001-02-15

Family

ID=27542219

Family Applications (2)

Application Number Title Priority Date Filing Date
AT86907184T ATE140009T1 (de) 1985-11-19 1986-11-19 Interleukin-4 protein mit bcgf- und tcgf- aktivität gegenüber menschlichen zellen (menschliches interleukin-4)
AT95108150T ATE198754T1 (de) 1985-11-19 1986-11-19 Antikörper gegen saugetier-interleukin-4 und peptide verwendbar als antigenen für deren herstellung

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT86907184T ATE140009T1 (de) 1985-11-19 1986-11-19 Interleukin-4 protein mit bcgf- und tcgf- aktivität gegenüber menschlichen zellen (menschliches interleukin-4)

Country Status (22)

Country Link
EP (3) EP0230107A1 (de)
JP (2) JP2557361B2 (de)
KR (1) KR940007773B1 (de)
CN (1) CN1020472C (de)
AT (2) ATE140009T1 (de)
AU (1) AU610057B2 (de)
CZ (1) CZ414191A3 (de)
DE (2) DE3650751T2 (de)
DK (1) DK371087A (de)
ES (2) ES2088858T3 (de)
FI (1) FI102075B (de)
GR (1) GR3021198T3 (de)
HU (1) HU208710B (de)
IE (1) IE80828B1 (de)
IL (1) IL80678A (de)
MY (1) MY101972A (de)
NO (1) NO301234B1 (de)
NZ (1) NZ218332A (de)
OA (1) OA08947A (de)
PT (1) PT83761B (de)
SK (1) SK414191A3 (de)
WO (1) WO1987002990A1 (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0740943B2 (ja) * 1985-09-30 1995-05-10 佑 本庶 新規なポリペプチドをコードするｄｎａ及びその製造方法
US5041381A (en) * 1986-07-03 1991-08-20 Schering Corporation Monoclonal antibodies against human interleukin-4 and hybridomas producing the same
US5700915A (en) * 1985-11-19 1997-12-23 Schering Corporations Human interleukin immunopurification processes
US5912136A (en) * 1985-11-19 1999-06-15 Schering Corporation Monoclonal antibodies against human interleukin-4 and hybridomas producing the same
US5082927A (en) * 1986-09-24 1992-01-21 The United States Of America As Represented By The Department Of Health And Human Services Selectively cytotoxic IL-4-PE40 fusion protein
WO1988004667A1 (en) * 1986-12-19 1988-06-30 Immunex Corporation Human interleukin-4 muteins
SE8701004D0 (sv) * 1987-03-11 1987-03-11 Astra Ab Method for therapy of leukemias and certain other malignancies
EP0301835A1 (de) * 1987-07-29 1989-02-01 Schering Biotech Corporation Reinigung von in Escherichia coli exprimiertem, menschlichem Interleukin-4
ES2059453T3 (es) * 1987-08-03 1994-11-16 Tasuku Honjo Un procedimiento para la produccion de interleuquina 4 humana.
JPH02485A (ja) * 1987-08-03 1990-01-05 Yuu Honshiyo 新規なヒトインターロイキン４、該因子を発現させるための組換えベクター及びそのベクターにより形質転換された形質転換体
WO1989006975A1 (en) * 1988-02-02 1989-08-10 Schering Biotech Corporation Method of reducing immunoglobulin e responses
GB8808015D0 (en) 1988-04-06 1988-05-05 Ritter M A Chemical compounds
GB2218420B (en) * 1988-04-12 1992-07-15 British Bio Technology Synthetic gene encoding interleukin 4
ATE140233T1 (de) * 1988-05-13 1996-07-15 University Patents Inc Von gemeinsamen sequenzen von antigenen und antiidiotypischen antikörpern oder von antikörpern mit spezifizität für die zellulären rezeptoren der antigene abgeleitete immunogene und biologisch aktive peptide
US4958007A (en) * 1988-05-17 1990-09-18 Schering-Plough Corp. Extraction of human interleukin-4- from bacteria
AU643427B2 (en) 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
AU4947090A (en) * 1988-12-21 1990-07-10 Schering Corporation Use of interleukin-4 for lowering blood glucose levels and/or effecting weight reduction
JPH0611706B2 (ja) * 1989-01-20 1994-02-16 ザ ユニバーシティ オブ メルボルン フィブリン溶解
US5077388A (en) * 1990-05-31 1991-12-31 Schering Corporation Purification of human interleukin-4 from a secreted escherichia coli mutant
AU635377B2 (en) * 1989-11-21 1993-03-18 University Of Melbourne, The Anti-inflammatory compositions and methods
SE465039B (sv) * 1989-11-23 1991-07-15 Chemrec Ab Saett att framstaella koklutar med hoeg sulfiditet foer sulfatmassakokning
US5188827A (en) * 1989-12-18 1993-02-23 Schering Corporation Use of interleukin-4- for lowering blood-cholesterol levels
DE69026627T2 (de) * 1989-12-20 1996-08-22 Schering Corp., Kenilworth, N.J. Antikörperantagonisten gegen humanes interleukin-4
ES2082201T3 (es) * 1990-03-21 1996-03-16 Schering Corp Uso de il-4 para mejorar la respuesta inmune a las pruebas de antigenos infecciosos.
ES2079851T3 (es) * 1990-12-19 1996-01-16 Schering Corp Uso de il-4 para mejorar la respuesta inmunitaria frente a inmunogenos en vacunas.
DK0566661T3 (da) * 1991-01-10 1996-07-01 Schering Corp Anvendelse af IL-4 til forstærkning af den reparative fase af sårheling og -reparation og til forstærkning af helingen af inficerede sår og sår hos diabetiske pattedyr
US5494662A (en) * 1992-04-27 1996-02-27 Ono Pharmaceutical Co., Ltd. Stimulator for bone formation
US5716612A (en) * 1994-09-07 1998-02-10 Schering Corporation Use of IL-4 for potentiation of chemotherapeutic agents
AUPN481295A0 (en) * 1995-08-16 1995-09-07 Medvet Science Pty. Ltd. Agonists of haemopoietic growth factors
US5986059A (en) * 1996-06-14 1999-11-16 Bayer Corporation T-cell selective interleukin-4 agonists
US6335426B1 (en) 1996-06-14 2002-01-01 Bayer Corporation T-cell selective interleukin-4 agonists
US6028176A (en) * 1996-07-19 2000-02-22 Bayer Corporation High-affinity interleukin-4 muteins
JP2003520940A (ja) * 1998-05-12 2003-07-08 アイシス・ファーマシューティカルス・インコーポレーテッド Ｒｎａその他の生体分子の分子相互作用部位の修飾
AUPQ005399A0 (en) * 1999-04-29 1999-05-27 Medvet Science Pty. Ltd. Agonists or antagonists for haemopoietic growth factors
WO2015089217A2 (en) 2013-12-10 2015-06-18 Bionz, Llc Methods of developing selective peptide antagonists
CN103501805B (zh) 2011-01-18 2018-09-14 比奥尼斯有限责任公司 调节γ-C-细胞因子活性的组合物及方法
CN102212888A (zh) * 2011-03-17 2011-10-12 靳海峰 一种基于高通量测序的免疫组库构建方法
PT3359556T (pt) 2015-10-09 2021-08-30 Bioniz Llc Modulação da atividade de citocinas gama-c
CN113874075A (zh) 2019-05-03 2021-12-31 比奥尼斯有限责任公司 调节γC-细胞因子信号传导对于治疗脱发和脱发相关病症的影响

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US799668A (en) * 1905-05-29 1905-09-19 Albert R Pritchard Dough kneader and mixer.
US799669A (en) * 1905-07-27 1905-09-19 Eugene S Regnier Combined cutting and raking implement.
US843958A (en) * 1905-11-20 1907-02-12 Whitehead & Hoag Co Key-ring tag.
US4613459A (en) * 1982-10-20 1986-09-23 Dana-Farber Cancer Institute Lymphocyte growth factor
US4695542A (en) * 1983-10-04 1987-09-22 Dnax Research Institute Of Molecular And Cellular Biology, Inc. cDNA clones coding for polypeptides exhibiting multi-lineage cellular growth factor activity
WO1987004723A1 (en) * 1986-02-11 1987-08-13 Board Of Regents, The University Of Texas System Recombinant human b-cell growth factor
ZA872781B (en) * 1986-05-19 1987-10-05 Immunology Ventures B-cell stimulating factor
WO1988004667A1 (en) * 1986-12-19 1988-06-30 Immunex Corporation Human interleukin-4 muteins

Also Published As

Publication number Publication date
NO301234B1 (no) 1997-09-29
EP0675136A2 (de) 1995-10-04
HK1005594A1 (en) 1999-01-15
IE863042L (en) 1987-05-19
WO1987002990A1 (en) 1987-05-21
DE3650538D1 (de) 1996-08-08
IL80678A (en) 1999-05-09
FI102075B1 (fi) 1998-10-15
FI873141A0 (fi) 1987-07-16
DE3650751T2 (de) 2001-08-02
AU610057B2 (en) 1991-05-16
DE3650538T2 (de) 1996-12-12
DE3650751D1 (de) 2001-02-22
IL80678A0 (en) 1987-02-27
CZ414191A3 (en) 1993-04-14
FI873141L (fi) 1987-07-16
CN86108579A (zh) 1988-01-27
ES2153444T3 (es) 2001-03-01
MY101972A (en) 1992-02-29
NO872988D0 (no) 1987-07-17
NZ218332A (en) 1993-04-28
EP0230107A1 (de) 1987-07-29
HUT43630A (en) 1987-11-30
DK371087A (da) 1987-09-21
IE80828B1 (en) 1999-03-10
OA08947A (en) 1990-11-30
EP0249613B1 (de) 1996-07-03
JPH0884591A (ja) 1996-04-02
ATE140009T1 (de) 1996-07-15
ES2088858T3 (es) 1996-10-01
AU6733487A (en) 1987-06-02
CN1020472C (zh) 1993-05-05
DK371087D0 (da) 1987-07-16
KR940007773B1 (ko) 1994-08-25
JP2557361B2 (ja) 1996-11-27
PT83761B (pt) 1989-06-30
FI102075B (fi) 1998-10-15
JPS63501401A (ja) 1988-06-02
PT83761A (en) 1986-12-01
NO872988L (no) 1987-09-18
EP0675136A3 (de) 1996-03-13
HK1008823A1 (en) 1999-05-21
EP0249613A1 (de) 1987-12-23
HU208710B (en) 1993-12-28
GR3021198T3 (en) 1996-12-31
EP0675136B1 (de) 2001-01-17
JP2568394B2 (ja) 1997-01-08
SK414191A3 (en) 1995-07-11

Similar Documents

Publication Publication Date Title
ATE198754T1 (de) Antikörper gegen saugetier-interleukin-4 und peptide verwendbar als antigenen für deren herstellung
ATE246246T1 (de) Herstellung von hämoglobin und analogen davon in nicht-erythrozytzellen
ATE91714T1 (de) Transformation von trichoderma.
DE68918867D1 (de) Mutanten des hiv-1 Hüllproteins mit fehlenden hypervariabelen domänen.
ATE232237T1 (de) Herstellung von funktionellen, menschlichen urokinaseproteinen
NO882946D0 (no) Konstruksjon av syntetisk dna og anvendelse derav i syntese av store polypeptider.
ES2120964T3 (es) Peptidos osteogenicos.
DE68928380D1 (de) Expression von menschlichen Serumalbumin in methylotrophischen Hefen
ATE206435T1 (de) Toxoplasma gondii-antigene, ihre herstellung und ihre verwendung
DE3881023D1 (de) Proteine, expressionsvektoren, die fuer solche proteine kodierende dna enthalten und zellen, die solche expressionsvektoren enthalten.
ES2085329T3 (es) Agente anticanceroso proteico.
ES2052513T3 (es) Nuevos polipeptidos, su fabricacion y empleo.
EP0676413A3 (de) Interferon alpha/beta bindendes Protein, seine Herstellung und Anwendung.
ATE130872T1 (de) Ancrod ähnliche proteine, ihre herstellung und verwendung.
ATE110112T1 (de) Verfahren und systeme zur herstellung von hiv- antigenen.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties